|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.03 USD | +1.80% |
|
+5.93% | +4.31% |
| 12:04am | OPKO Health Raises $250 Million Non-Dillutive Capital Via Note Issue | MT |
| 17/07 | Mark Cuban's Cost Plus to import penicillin to address US shortage | RE |
(Reuters) - Pfizer Inc on Tuesday forecast 2023 sales of its COVID-19 products that fell short of Wall Street expectations, hit by lower demand in international markets and slower uptake of booster vaccines.
The U.S. drugmaker said it expects sales of $13.5 billion from the vaccine for 2023, below Refinitiv estimates of $14.39 billion, and projected $8 billion in sales of its antiviral pill, Paxlovid, short of $10.33 billion the Street expects.
(Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)
| 1st Jan change | Capi. | |
|---|---|---|
| +4.31% | 167B | |
| +55.35% | 848B | |
| +31.64% | 627B | |
| -0.10% | 363B | |
| +15.47% | 318B | |
| +13.10% | 299B | |
| +15.51% | 243B | |
| +16.72% | 225B | |
| +16.54% | 179B | |
| +2.52% | 125B |
PFIZER, INC. 
